Making Healthy Habits Stick
NCT06745180
Recruiting
The aim of this project is to help increase physical activity maintenance in cancer survivors who are more likely to experience health disparities and social disadvantages.
Gender:
FEMALE
Ages:
Between 19 years and 89 years
Trial Updated:
05/19/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +1 locations
Conditions: Cancer, Physical Activity, Cancer Survivor, Cancer Survivorship
Register for Updates
Response to an Investigational Device in Patients With Restless Legs Syndrome
NCT06866132
Recruiting
This study assesses the tolerability, safety, and impact of an investigational medical device on restless legs syndrome symptoms. The IRB has established that the investigational device is non-significant risk.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
05/19/2025
Locations: Noctrix Health Headquarters, Pleasanton, California
Conditions: Restless Legs Syndrome
Register for Updates
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
NCT03587701
Recruiting
A Phase II randomized, placebo controlled study design of anakinra (Kineret) in corticosteroid-resistant or intolerant Meniere's disease (CR-MD)and corticosteroid-resistant or intolerant autoimmune inner ear disease (CR-AIED) patients. Patients will be randomized by a 2:1 allocation to anakinra or placebo for 42 continuous days. After day 42, a second placebo-controlled period will begin for an additional 42 days. This will be followed by a 264 day observation period, during which, hearing decli... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/19/2025
Locations: Northwell Health, Hearing& Speech Center, New Hyde Park, New York
Conditions: Autoimmune Inner Ear Disease, Meniere's Disease
Register for Updates
Pilot Study of PHOENIX Wound Matrix® Impact on Chronic DFU Wound Microbiome
NCT04437537
Recruiting
A Pilot Study to Determine the Impact of the Phoenix Wound Matrix® on the Wound Microbiome in Chronic Diabetic Foot Ulcers
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: PA Foot & Ankle Associates, Northampton, Pennsylvania
Conditions: Diabetic Foot Ulcer
Register for Updates
Addressing Disparities in Autism Spectrum Disorder Diagnosis Using a Direct-to-home Telemedicine Tool
NCT05047224
Recruiting
The investigators propose to evaluate the use of a telemedicine tool, the TELE-ASD-PEDS (TAP), that is designed to assess for autism spectrum disorder (ASD) symptoms in toddlers. The TAP was developed at VUMC by a team of clinical psychologists with expertise in the early identification of ASD. The TAP has been studied in controlled laboratory settings, with high levels of family and clinician satisfaction, as well as excellent agreement with blinded comprehensive ASD evaluation. The TAP has als... Read More
Gender:
ALL
Ages:
Between 18 months and 42 months
Trial Updated:
05/19/2025
Locations: UC Davis MIND Institute, Sacramento, California
Conditions: Autism Spectrum Disorder
Register for Updates
R21: An Easy-to-use, iNtelligent, Affordable LinEr (ENABLE) System for Socket Fit Assessment
NCT05425810
Recruiting
Lower limb amputees (LLA) rely on their prosthetic legs to remain active and lead an independent life. For most LLAs, a well-fitted prosthetic socket is the only option to interface with their prosthetic leg, however, it is a real challenge to make a prosthetic socket to interface with residual limbs accurately. One of the reasons is that there lack of accurate approaches to evaluate the pressure distribution on the residual limb accurately and effectively. To overcome this issue, the research t... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
05/19/2025
Locations: NC State University, Raleigh, North Carolina
Conditions: Lower Limb Amputation Below Knee (Injury)
Register for Updates
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
NCT05683171
Recruiting
To find a recommended dose of valemetostat that can be given in combination with rituximab and lenalidomide to patients with follicular lymphoma. The safety and effects of this drug combination will also be studied
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma
Register for Updates
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06031441
Recruiting
This is a first-in-human Phase I, open-label, dose-escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamic, and preliminary anti-tumor activity of RO7566802 as a single agent and in combination with atezolizumab in participants with locally advanced, recurrent, or metastatic incurable solid tumor malignancies. Participants will be enrolled in 2 stages: dose escalation and expansion.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: University of Alabama at Birmingham (UAB), Birmingham, Alabama +10 locations
Conditions: Locally Advanced Solid Tumors, Recurrent Solid Tumors, Metastatic Solid Tumors
Register for Updates
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
NCT06226883
Recruiting
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 2 active dose regimens of MORF-057 in adult study participants with moderately to severely active Crohn's disease (CD).
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
05/19/2025
Locations: Clinical Study Site, Lancaster, California +138 locations
Conditions: Inflammatory Bowel Diseases, Crohn's Disease
Register for Updates
Optimizing Pulsatility During Cardiopulmonary Bypass to Reduce Acute Kidney Injury
NCT06349577
Recruiting
The objective is to determine the effectiveness of pulsatile flow during cardiopulmonary bypass to reduce the incidence of acute kidney injury after cardiac surgery. Investigators will also evaluate the safety and impact of pulsatile flow on clinical outcomes compared to non-pulsatile flow during cardiopulmonary bypass.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
05/19/2025
Locations: University of Colorado Hospital, Aurora, Colorado
Conditions: Acute Kidney Injury, Hemolysis, Thrombocytopenia, Surgery
Register for Updates
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
NCT06472245
Recruiting
Multicenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI secondary resistance. Patients will be randomized into 2 arms (randomization 2:1): experimental Arm A with OSE2101 monotherapy or control Arm B SoC with docetaxel monotherapy. Stratification factors will be histology (squamous versus non squamous) and ECOG Performance Status (0 versus 1).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Clinical Research Advisors, LLC, Beverly Hills, California +204 locations
Conditions: Patients With Non-Small Cell Lung Cancer
Register for Updates
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
NCT06576037
Recruiting
An open-label, Phase Ib dose escalation and dose expansion clinical trial evaluating the safety and efficacy of CBP-1019 combinations in patients with solid tumors of epithelial origin.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Solid Tumor
Register for Updates